Newron’s Steep Descent Accelerates as Evenamide Hopes Hinge on Conference Circuit

The sell-off in Newron Pharmaceuticals has shown no signs of letting up. Shares closed last Friday at €13.15, marking a 13.4% decline over the preceding seven days and a loss of more than 50% since the start of the year. The stock now sits more than 61% below its January peak of €34.15, a level that, at the time, had investors betting on a breakthrough from the company’s lead schizophrenia candidate.

There is no single catalyst behind the latest leg lower. Instead, the downtrend that took hold in late winter has simply tightened its grip, pushing the equity further away from its key moving averages. At current prices, Newron trades roughly 17% below its 50-day average of €15.91 and almost 30% beneath the 200-day line of €18.31. The relative strength index, at 35.2, is flirting with oversold territory but has yet to generate a trend-reversal signal.

The pullback could hardly have come at a more awkward time for management. Chief Executive Stefan Weber and Chief Financial Officer Roberto Galli were in New York on June 4 for the Jefferies Global Healthcare Conference, a gathering of biotech, medtech and pharma executives. Alongside a public presentation, the pair held one-on-one meetings with institutional investors, seeking to shore up confidence in the pipeline. The annualised 30-day volatility of more than 72% underscores just how sensitive the stock remains to news flow.

The entire investment case, for now, rests on the clinical programme for Evenamide. Newron is developing the central nervous system candidate as an add-on therapy for treatment-resistant schizophrenia in the global Phase III ENIGMA-TRS study. The company’s financial position reflects that stage of development: research and development spending rose to €15.1 million in 2025 from €13.6 million a year earlier, while the net loss widened to €13.2 million. In 2024, by contrast, Newron booked a net profit of €15.8 million, though that was inflated by a one-time payment from the EA-Pharma agreement signed in December of that year.

Should investors sell immediately? Or is it worth buying Newron SpA?

The balance sheet, however, provides a cushion. Newron ended 2025 with €28.9 million in cash and short-term financial assets, up from €9.8 million at the start of the year. That liquidity gives the company some breathing room as it awaits the next batch of clinical data.

Longer-term holders have not been wiped out entirely — those who bought a year ago are still up by roughly 69%. But the turnaround that began in early 2025 has vanished, and the speed of the reversal has been brutal.

Management will get another chance to reset the narrative later this month. Starting June 15, a presentation for the H.C. Wainwright Neuro Perspectives Conference will be made available, again accompanied by one-on-one investor meetings. The key question is whether the company can deliver concrete progress updates on the ENIGMA-TRS programme, rather than the usual conference-circuit boilerplate. Without a material catalyst, the technical picture suggests the path of least resistance remains lower.